Regenerative Medical Technology Group Profit Margin

Regenerative Medical Technology Group (RMTG) currently reports a profit margin of -101.21% as of June 2026. That compares with -74.12% in the prior-year period — down 36.5% year over year. That is below the Healthcare sector average of 9.48%. Use the charts on this page to explore Regenerative Medical Technology Group's profit margin history and peer comparisons.

Regenerative Medical Technology Group's profit margin decreased from -74.12% to -101.21% — a 36.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Regenerative Medical Technology Group's profit margin of -101.21% is lower than the Healthcare sector average of 9.48%. That is roughly 1167.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Regenerative Medical Technology Group's current -101.21% should be judged against Healthcare norms (sector average: 9.48%) and against RMTG's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -101.21%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.48%. From there, open related valuation or income-statement pages for Regenerative Medical Technology Group, and consider following RMTG for alerts when major investors trade the stock.